Pnc Financial Services Group, Inc. Cyma Bay Therapeutics, Inc. Transaction History

Pnc Financial Services Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$12.63 - $24.47 $97,958 - $189,789	7,756 Added 1833.57%	8,179 $193,000
Q3 2023 Nov 13, 2023	BUY	$10.86 - $17.62 $4,593 - $7,453	423 New	423 $6,000
Q2 2022 Aug 12, 2022	SELL	$1.72 - $3.39 $760 - $1,498	-442 Closed	0 $0
Q1 2020 May 08, 2020	SELL	$1.25 - $2.02 $152 - $246	-122 Reduced 21.63%	442 $0
Q4 2019 Feb 07, 2020	BUY	$1.33 - $5.93 $702 - $3,131	528 Added 1466.67%	564 $1,000
Q3 2019 Nov 08, 2019	BUY	$5.12 - $7.21 $184 - $259	36 New	36 $0
Q2 2019 Aug 09, 2019	SELL	$6.05 - $13.66 $62,073 - $140,151	-10,260 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$8.16 - $13.42 $23,337 - $38,381	-2,860 Reduced 21.8%	10,260 $0
Q4 2018 Feb 08, 2019	BUY	$6.54 - $11.74 $16,088 - $28,880	2,460 Added 23.08%	13,120 $103,000
Q3 2018 Nov 09, 2018	SELL	$10.88 - $14.52 $7,616 - $10,164	-700 Reduced 6.16%	10,660 $0
Q2 2018 Aug 10, 2018	BUY	$10.66 - $14.38 $121,097 - $163,356	11,360 New	11,360 $0

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.